FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1989527253> ?p ?o ?g. }

• W1989527253 endingPage "704" @default.
• W1989527253 startingPage "704" @default.
• W1989527253 abstract "JAMA Discontinuation of Anticytomegalovirus Therapy in Patients With HIV Infection and Cytomegalovirus Retinitis Scott M. Whitcup, MD; Eric Fortin, MD; Anne S. Lindblad, PhD; Paul Griffiths, MD; Julia A. Metcalf, BA; Michael R. Robinson, MD; Jody Manischewitz, MS; Barbara Baird, RN; Cheryl Perry, RN; I. Michael Kidd, PhD; Tamara Vrabec, MD; Richard T. Davey, Jr, MD; Judith Falloon, MD; Robert E. Walker, MD; Joseph A. Kovacs, MD; H. Clifford Lane, MD; Robert B. Nussenblatt, MD; Janine Smith, MD; Henry Masur, MD; Michael A. Polis, MD Context Persons with cytomegalovirus (CMV) retinitis and acquired immunodeficiency syndrome (AIDS) have required lifelong anti-CMV therapy to prevent the progression of retinal disease and subsequent loss of vision. Objective To determine whether patients who were taking highly active antiretroviral therapy (HAART) and who had stable CMV retinitis could safely discontinue anti-CMV therapy without reactivation of their retinitis or increase in human immunodeficiency virus (HIV) viral load. Design Prospective nonrandomized interventional trial performed from July 1997 to August 1999. Setting Clinical Center of the National Institutes of Health, Bethesda, Md. Patients Fourteen patients with stable CMV retinitis and HIV infection and CD4 + cell counts higher than 0.15 × 10 9 /L and being treated with systemic anti-CMV medications and HAART. Interventions Discontinuation of specific anti-CMV therapy. Main Outcome Measures Reactivation of CMV retinitis, development of extraocular CMV infection, detection of CMV in blood and urine, HIV burden, immunologic function, quality of life, morbidity, and mortality. Results Twelve (89.7%) of 14 patients had evidence of immune recovery uveitis before anti-CMV drugs were discontinued. No patient had reactivation of CMV retinitis or development of extraocular CMV disease during mean follow-up of 16.4 months (range, 8.3-22.0 months) without anti-CMV therapy. Human immunodeficiency viral load remained stable following cessation of anti-CMV medications. Blood and urine assays for CMV were briefly positive in 9 patients but did not predict reactivation of CMV disease. Worsening immune recovery uveitis was associated with a substantial (>3 lines) vision loss in 3 patients. Conclusions Maintenance anti-CMV medications were safely stopped in those patients who had stable CMV retinitis and elevated CD4 + cell counts and who were taking HAART. The study demonstrates that immune recovery following potent antiretroviral therapy is effective in controlling a major opportunistic infection, even in patients with a history of severe immunosuppression. 1999;282:1633-1637." @default.
• W1989527253 created "2016-06-24" @default.
• W1989527253 creator A5022183607 @default.
• W1989527253 date "2000-05-01" @default.
• W1989527253 modified "2023-09-27" @default.
• W1989527253 title "New Issues in the Management of Patients With AIDS-Related Cytomegalovirus Retinitis" @default.
• W1989527253 cites W1834441530 @default.
• W1989527253 cites W2005218469 @default.
• W1989527253 cites W2052181220 @default.
• W1989527253 cites W2071751392 @default.
• W1989527253 cites W2082182354 @default.
• W1989527253 cites W2093607628 @default.
• W1989527253 cites W2101739571 @default.
• W1989527253 cites W2133556476 @default.
• W1989527253 doi "https://doi.org/10.1001/archopht.118.5.704" @default.
• W1989527253 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10815164" @default.
• W1989527253 hasPublicationYear "2000" @default.
• W1989527253 type Work @default.
• W1989527253 sameAs 1989527253 @default.
• W1989527253 citedByCount "4" @default.
• W1989527253 countsByYear W19895272532016 @default.
• W1989527253 crossrefType "journal-article" @default.
• W1989527253 hasAuthorship W1989527253A5022183607 @default.
• W1989527253 hasConcept C159047783 @default.
• W1989527253 hasConcept C2522874641 @default.
• W1989527253 hasConcept C2776409557 @default.
• W1989527253 hasConcept C2777016524 @default.
• W1989527253 hasConcept C2777324356 @default.
• W1989527253 hasConcept C2777732132 @default.
• W1989527253 hasConcept C2779820661 @default.
• W1989527253 hasConcept C2780727368 @default.
• W1989527253 hasConcept C3013748606 @default.
• W1989527253 hasConcept C71924100 @default.
• W1989527253 hasConceptScore W1989527253C159047783 @default.
• W1989527253 hasConceptScore W1989527253C2522874641 @default.
• W1989527253 hasConceptScore W1989527253C2776409557 @default.
• W1989527253 hasConceptScore W1989527253C2777016524 @default.
• W1989527253 hasConceptScore W1989527253C2777324356 @default.
• W1989527253 hasConceptScore W1989527253C2777732132 @default.
• W1989527253 hasConceptScore W1989527253C2779820661 @default.
• W1989527253 hasConceptScore W1989527253C2780727368 @default.
• W1989527253 hasConceptScore W1989527253C3013748606 @default.
• W1989527253 hasConceptScore W1989527253C71924100 @default.
• W1989527253 hasIssue "5" @default.
• W1989527253 hasLocation W19895272531 @default.
• W1989527253 hasLocation W19895272532 @default.
• W1989527253 hasOpenAccess W1989527253 @default.
• W1989527253 hasPrimaryLocation W19895272531 @default.
• W1989527253 hasRelatedWork W2011378222 @default.
• W1989527253 hasRelatedWork W2026278450 @default.
• W1989527253 hasRelatedWork W2052154249 @default.
• W1989527253 hasRelatedWork W2091396445 @default.
• W1989527253 hasRelatedWork W2134301300 @default.
• W1989527253 hasRelatedWork W2416802537 @default.
• W1989527253 hasRelatedWork W2418859838 @default.
• W1989527253 hasRelatedWork W2892194051 @default.
• W1989527253 hasRelatedWork W2986904068 @default.
• W1989527253 hasRelatedWork W4249253247 @default.
• W1989527253 hasVolume "118" @default.
• W1989527253 isParatext "false" @default.
• W1989527253 isRetracted "false" @default.
• W1989527253 magId "1989527253" @default.
• W1989527253 workType "article" @default.